This HTML5 document contains 111 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n8http://linked.opendata.cz/resource/drugbank/drug/DB01150/identifier/kegg-compound/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n22http://linked.opendata.cz/resource/AHFS/
n16http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n13http://linked.opendata.cz/resource/drugbank/company/
n4http://linked.opendata.cz/resource/drugbank/dosage/
n6http://linked.opendata.cz/resource/drugbank/drug/DB01150/identifier/drugbank/
n12http://bio2rdf.org/drugbank:
n9http://linked.opendata.cz/resource/drugbank/drug/DB01150/identifier/national-drug-code-directory/
admshttp://www.w3.org/ns/adms#
n27http://www.rxlist.com/cgi/generic/
n25http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n21http://linked.opendata.cz/resource/drugbank/medicinal-product/
n7http://linked.opendata.cz/resource/drugbank/drug/DB01150/identifier/chebi/
owlhttp://www.w3.org/2002/07/owl#
n15http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n26http://www.drugs.com/cdi/
n10http://linked.opendata.cz/resource/drugbank/property/
n20http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n24http://linked.opendata.cz/resource/drugbank/drug/DB01150/identifier/wikipedia/
n23http://linked.opendata.cz/resource/drugbank/drug/DB01150/identifier/pharmgkb/
n18http://linked.opendata.cz/resource/atc/
n17http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01150
rdf:type
n3:Drug
n3:description
Cefprozil is a cephalosporin antibiotic. It can be used to treat bronchitis, ear infections, skin infections, and other bacterial infections.
n3:dosage
n4:271B49CB-363D-11E5-9242-09173F13E4C5 n4:271B49CC-363D-11E5-9242-09173F13E4C5 n4:271B49CD-363D-11E5-9242-09173F13E4C5 n4:271B49CE-363D-11E5-9242-09173F13E4C5 n4:271B49CF-363D-11E5-9242-09173F13E4C5 n4:271B49D0-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
1.3 hours
n3:indication
For the treatment of the following infections (respiratory, skin, soft tissue, UTI, ENT) caused by; S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staph
owl:sameAs
n12:DB01150 n25:DB01150
dcterms:title
Cefprozil
adms:identifier
n6:DB01150 n7:3506 n8:C06888 n9:0087-7720-60 n23:PA164746342 n24:Cefprozil
n3:mechanismOfAction
Cefprozil, like the penicillins, is a beta-lactam antibiotic. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cefprozil interferes with an autolysin inhibitor.
n3:packager
n13:271B49B0-363D-11E5-9242-09173F13E4C5 n13:271B49AE-363D-11E5-9242-09173F13E4C5 n13:271B49AF-363D-11E5-9242-09173F13E4C5 n13:271B49AC-363D-11E5-9242-09173F13E4C5 n13:271B49B6-363D-11E5-9242-09173F13E4C5 n13:271B49AD-363D-11E5-9242-09173F13E4C5 n13:271B49B4-363D-11E5-9242-09173F13E4C5 n13:271B49B5-363D-11E5-9242-09173F13E4C5 n13:271B49B2-363D-11E5-9242-09173F13E4C5 n13:271B49B3-363D-11E5-9242-09173F13E4C5 n13:271B49B1-363D-11E5-9242-09173F13E4C5 n13:271B49AA-363D-11E5-9242-09173F13E4C5 n13:271B49AB-363D-11E5-9242-09173F13E4C5 n13:271B49A8-363D-11E5-9242-09173F13E4C5 n13:271B49A9-363D-11E5-9242-09173F13E4C5 n13:271B49A6-363D-11E5-9242-09173F13E4C5 n13:271B49A7-363D-11E5-9242-09173F13E4C5 n13:271B49A4-363D-11E5-9242-09173F13E4C5 n13:271B49A5-363D-11E5-9242-09173F13E4C5
n3:synonym
Cefprozilum Cefprozil Cefzil Cefprozil anhydrous Cefprozilo
n3:toxicity
Single 5000 mg/kg oral doses of cefprozil caused no mortality or signs of toxicity in adult, weaning or neonatal rats, or adult mice. A single oral dose of 3000 mg/kg caused diarrhea and loss of appetite in cynomolgus monkeys, but no mortality.
n3:volumeOfDistribution
* 0.23 L/kg
n17:hasAHFSCode
n22:08-12-06-08
n3:foodInteraction
Take without regard to meals.
n3:proteinBinding
36%
n3:salt
n3:synthesisReference
Julia Greil, Johannes Ludescher, Siegfried Wolf, "Intermediates in cefprozil production." U.S. Patent US07355041, issued April 08, 2008.
n15:hasConcept
n16:M0147833
foaf:page
n20:cef1077.shtml n26:cefprozil.html n27:cefprozi.htm
n3:IUPAC-Name
n10:271B49D5-363D-11E5-9242-09173F13E4C5
n3:InChI
n10:271B49DB-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n10:271B49DA-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n10:271B49D7-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n10:271B49D8-363D-11E5-9242-09173F13E4C5
n3:SMILES
n10:271B49D9-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n10:271B49D3-363D-11E5-9242-09173F13E4C5 n10:271B49EB-363D-11E5-9242-09173F13E4C5
n3:logP
n10:271B49D1-363D-11E5-9242-09173F13E4C5 n10:271B49D4-363D-11E5-9242-09173F13E4C5 n10:271B49ED-363D-11E5-9242-09173F13E4C5
n3:logS
n10:271B49D2-363D-11E5-9242-09173F13E4C5
n17:hasATCCode
n18:J01DC10
n3:H-Bond-Acceptor-Count
n10:271B49E1-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n10:271B49E2-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n10:271B49DC-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n10:271B49DD-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n10:271B49DF-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n10:271B49DE-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n10:271B49E0-363D-11E5-9242-09173F13E4C5
n3:absorption
Oral bioavailability is approximately 95%.
n3:affectedOrganism
Enteric bacteria and other eubacteria
n3:casRegistryNumber
92665-29-7
n3:category
n3:clearance
* 3 mL/min/kg [fasting subjects]
n3:containedIn
n21:271B49BA-363D-11E5-9242-09173F13E4C5 n21:271B49BB-363D-11E5-9242-09173F13E4C5 n21:271B49CA-363D-11E5-9242-09173F13E4C5 n21:271B49C8-363D-11E5-9242-09173F13E4C5 n21:271B49C9-363D-11E5-9242-09173F13E4C5 n21:271B49C6-363D-11E5-9242-09173F13E4C5 n21:271B49C7-363D-11E5-9242-09173F13E4C5 n21:271B49C4-363D-11E5-9242-09173F13E4C5 n21:271B49C5-363D-11E5-9242-09173F13E4C5 n21:271B49C2-363D-11E5-9242-09173F13E4C5 n21:271B49C3-363D-11E5-9242-09173F13E4C5 n21:271B49C0-363D-11E5-9242-09173F13E4C5 n21:271B49C1-363D-11E5-9242-09173F13E4C5 n21:271B49BE-363D-11E5-9242-09173F13E4C5 n21:271B49BF-363D-11E5-9242-09173F13E4C5 n21:271B49BC-363D-11E5-9242-09173F13E4C5 n21:271B49BD-363D-11E5-9242-09173F13E4C5 n21:271B49B9-363D-11E5-9242-09173F13E4C5 n21:271B49B7-363D-11E5-9242-09173F13E4C5 n21:271B49B8-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n10:271B49E7-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n10:271B49E9-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n10:271B49EA-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n10:271B49EC-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n10:271B49E6-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n10:271B49E5-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n10:271B49E8-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n10:271B49D6-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n10:271B49E3-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n10:271B49E4-363D-11E5-9242-09173F13E4C5